Huntington's Disease Treatment Market Analysis

Drugs (Tetrabenazine, Deutetrabenazine, Other Drugs)

The tetrabenazine segment in huntington’s disease treatment market registered the highest market share of 53.6% in 2024 and is poised to increase its revenue share by the end of 2037. The segment’s growth is attributed to its effectiveness in managing chorea, a common HD symptom. It is the first Food and Drug Administration (FDA) approved drug specifically designed to manage chorea and has solidified as a go-to drug for HD treatment by managing symptoms.

Tetrabenazine reduces excessive dopamine activity in the brain and manages involuntary movements of HD patients. Additionally, the rising awareness on HD treatment has led to a boost in the demand for symptom management medications. In the future, novel HD treatment solutions with tetrabenazine involving lesser side effects is poised to open new opportunities within the segment and continue increasing the revenue share.

Deutetrabenazine is a rapidly growing segment in the huntington’s disease treatment market that is estimated to significantly increase its revenue share by the end of 2037. In February 2023, Austedo XR or Deutetrabenazine was approved by the FDA to be administered as extended-release tablets. Deutetrabenazine is used to manage chorea in HD patients by suppressing dopamine activity in the brain. The segment’s growth is attributed to the longer half-life that allows stable symptom control with fewer doses and ability to reduce side effects such as fatigue and depression. Additionally, increased diagnosis of HD due to rising awareness has led to greater adoption of deutetrabenazine boosting the segment’s growth.

Type (Branded, Generic)

The branded segment in huntington’s disease treatment market is witnessing steady growth and is estimated to improve the revenue share by 2037. The segment’s growth is owed to Xenazine (Tetrabenazine) and Austedo (Deuterabenazine) that help manage symptoms of Huntington’s disease. The segment also benefits from growing awareness on the medications and increase in research & development activities by companies to develop therapies with greater efficacy. Branded drugs have the benefit of safety profiles and instill confidence in buyers compared to generic drugs. The segment is poised to grow further as new drug formulations are researched and pass clinical trial, and approval.

Our in-depth analysis of the huntington’s disease treatment market includes the following segments: